Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 3.52
AVNR's Cash to Debt is ranked higher than
76% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. AVNR: 3.52 )
AVNR' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 3.52

Equity to Asset 0.56
AVNR's Equity to Asset is ranked higher than
64% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. AVNR: 0.56 )
AVNR' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.95
Current: 0.56

-0.16
0.95
F-Score: 5
Z-Score: 15.08
M-Score: -1.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -65.55
AVNR's Operating margin (%) is ranked higher than
51% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.55 vs. AVNR: -65.55 )
AVNR' s 10-Year Operating margin (%) Range
Min: -1373.1   Max: 35.08
Current: -65.55

-1373.1
35.08
Net-margin (%) -69.03
AVNR's Net-margin (%) is ranked higher than
50% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.99 vs. AVNR: -69.03 )
AVNR' s 10-Year Net-margin (%) Range
Min: -1389.34   Max: 1.84
Current: -69.03

-1389.34
1.84
ROE (%) -107.58
AVNR's ROE (%) is ranked lower than
55% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. AVNR: -107.58 )
AVNR' s 10-Year ROE (%) Range
Min: -8600   Max: 0.97
Current: -107.58

-8600
0.97
ROA (%) -60.60
AVNR's ROA (%) is ranked lower than
54% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. AVNR: -60.60 )
AVNR' s 10-Year ROA (%) Range
Min: -477.78   Max: 0.86
Current: -60.6

-477.78
0.86
ROC (Joel Greenblatt) (%) -1258.76
AVNR's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.22 vs. AVNR: -1258.76 )
AVNR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7049.84   Max: 342.25
Current: -1258.76

-7049.84
342.25
Revenue Growth (%) 160.40
AVNR's Revenue Growth (%) is ranked higher than
99% of the 670 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. AVNR: 160.40 )
AVNR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 160.4
Current: 160.4

0
160.4
EBITDA Growth (%) 18.60
AVNR's EBITDA Growth (%) is ranked higher than
83% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. AVNR: 18.60 )
AVNR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 223.2
Current: 18.6

0
223.2
EPS Growth (%) 20.90
AVNR's EPS Growth (%) is ranked higher than
84% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. AVNR: 20.90 )
AVNR' s 10-Year EPS Growth (%) Range
Min: -67.9   Max: 238.4
Current: 20.9

-67.9
238.4
» AVNR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AVNR Guru Trades in Q3 2013

Steven Cohen 14,500 sh (New)
Paul Tudor Jones 42,100 sh (New)
» More
Q4 2013

AVNR Guru Trades in Q4 2013

Steven Cohen 22,061 sh (+52.14%)
Paul Tudor Jones Sold Out
» More
Q1 2014

AVNR Guru Trades in Q1 2014

Steven Cohen 25,798 sh (+16.94%)
» More
Q2 2014

AVNR Guru Trades in Q2 2014

Steven Cohen 201,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AVNR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 25.98
AVNR's P/B is ranked higher than
50% of the 828 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. AVNR: 25.98 )
AVNR' s 10-Year P/B Range
Min: 0.78   Max: 202.67
Current: 25.98

0.78
202.67
P/S 16.28
AVNR's P/S is ranked higher than
57% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. AVNR: 16.28 )
AVNR' s 10-Year P/S Range
Min: 2.23   Max: 116.75
Current: 16.28

2.23
116.75
EV-to-EBIT -26.13
AVNR's EV-to-EBIT is ranked higher than
55% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. AVNR: -26.13 )
AVNR' s 10-Year EV-to-EBIT Range
Min: 26.6   Max: 123.5
Current: -26.13

26.6
123.5
Current Ratio 3.06
AVNR's Current Ratio is ranked higher than
77% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. AVNR: 3.06 )
AVNR' s 10-Year Current Ratio Range
Min: 0.35   Max: 22.13
Current: 3.06

0.35
22.13
Quick Ratio 3.04
AVNR's Quick Ratio is ranked higher than
80% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. AVNR: 3.04 )
AVNR' s 10-Year Quick Ratio Range
Min: 0.29   Max: 22.13
Current: 3.04

0.29
22.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 51.96
AVNR's Price/Net Cash is ranked higher than
88% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AVNR: 51.96 )
AVNR' s 10-Year Price/Net Cash Range
Min: 1.64   Max: 400
Current: 51.96

1.64
400
Price/Net Current Asset Value 34.10
AVNR's Price/Net Current Asset Value is ranked higher than
85% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AVNR: 34.10 )
AVNR' s 10-Year Price/Net Current Asset Value Range
Min: 1.64   Max: 250
Current: 34.1

1.64
250
Price/Tangible Book 25.98
AVNR's Price/Tangible Book is ranked higher than
57% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.11 vs. AVNR: 25.98 )
AVNR' s 10-Year Price/Tangible Book Range
Min: 1.32   Max: 90.91
Current: 25.98

1.32
90.91
Price/Median PS Value 0.74
AVNR's Price/Median PS Value is ranked higher than
96% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. AVNR: 0.74 )
AVNR' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 58.82
Current: 0.74

0.18
58.82
Earnings Yield (Greenblatt) 0.30
AVNR's Earnings Yield (Greenblatt) is ranked lower than
55% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. AVNR: 0.30 )
AVNR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 3.8
Current: 0.3

0.3
3.8
Forward Rate of Return (Yacktman) 4.76
AVNR's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. AVNR: 4.76 )
AVNR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.8   Max: -0.5
Current: 4.76

-1.8
-0.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:AV2B.Germany
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a pharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an innovative combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.
» More Articles for AVNR

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Danaher Corporation, Orbitz Worldwide Inc., 3D Systems Corporation and A May 20 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 
Options V: Short-Term Strategy – Earning Money on Volatility Oct 19 2011 
Avanir Pharmaceuticals Reports Operating Results (10-Q) Feb 07 2011 
Avanir Pharmaceuticals Reports Operating Results (10-K) Dec 08 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 195,300 Shares Dec 03 2010 
Weekly CEO Sells Highlights: MAC, GNET, ASIA, and AVNR Sep 05 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 102,874 Shares Sep 02 2010 
Avanir Pharmaceuticals Reports Operating Results (10-Q) Aug 05 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 105,906 Shares May 04 2010 

More From Our Partners
Technology Stocks Down As Rest Of The Market Starts Week Flat Sep 15 2014 - BENZINGA

More From Other Websites
Avanir Pharmaceuticals Sep 15 2014
Most active Nasdaq-traded stocks Sep 15 2014
Technology Stocks Down As Rest Of The Market Starts Week Flat Sep 15 2014
[video] U.S. Stocks Close Mixed with Nasdaq Slammed by Sell-off Sep 15 2014
Alere and Avanir are big market movers Sep 15 2014
Alere and Avanir are big market movers Sep 15 2014
US STOCKS-Nasdaq slumps to worst day since July; S&P 500 dips Sep 15 2014
US STOCKS-Nasdaq slumps to worst day since July; S&P 500 dips Sep 15 2014
Taking Stock: Winners and Losers, Stock of the Day Sep 15 2014
Terex Falls After Lowered Earnings Forecast; Avanir Pharmaceuticals Shares Surge Sep 15 2014
US STOCKS-Tech shares drag Nasdaq, S&P 500 little changed Sep 15 2014
US STOCKS-Tech shares drag Nasdaq, S&P 500 little changed Sep 15 2014
Avanir Pharma soars on agitation drug study Sep 15 2014
Avanir Pharma soars on agitation drug study Sep 15 2014
NASDAQ Tumbles 1.1%; Alere Shares Surge Following Proposed $46/Share Offer Sep 15 2014
AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 15 2014
US STOCKS-Nasdaq loses ground as tech sector weighs Sep 15 2014
US STOCKS-Nasdaq loses ground as tech sector weighs Sep 15 2014
Midday Gainers From September 15 - RadioShack Corporation, Rewalk Robotics Ltd And More Sep 15 2014
Markets Fall; Cognizant To Acquire TriZetto For $2.7 Billion Sep 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK